Study of Early Aspirin Treatment After Hemorrhagic Infarction in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis in China

What this Trial Is About

Researchers are conducting a randomized clinical trial to study acute ischemic stroke patients who have experienced hemorrhagic infarction after intravenous thrombolysis. The trial aims to explore the safety and effectiveness of starting antiplatelet therapy early in these patients. Previous research showed that hemorrhagic infarction often occurs after this treatment but is mostly asymptomatic and not linked to worse outcomes. The study compares two approaches early antiplatelet therapy with aspirin given within 24 to 48 hours after stroke onset, and delayed antiplatelet therapy started beyond 48 hours or after hemorrhagic infarction has been confirmed absorbed. The aspirin dose will be determined by the clinician. Participants are randomly assigned to one of these two groups in a double-blind design. Participants will be monitored for several outcomes including the proportion with a favorable modified Rankin scale score at 90 days, changes in hemorrhage size at 7 days, stroke severity progress by NIHSS scores, and stroke recurrence rates up to one year. The trial includes clinical assessments, imaging at 24 to 36 hours post-thrombolysis, and follow-up visits to assess recovery and safety. The study is sponsored by the Second Affiliated Hospital, School of Medicine, Zhejiang University.

Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)